RSNA 2020 News

Ziosoft software peers into COVID-19 organ damage

By staff writers
December 1, 2020

Ziosoft is taking the opportunity at RSNA 2020 to show how its vendor-neutral 3D/4D visualization software is helpful for visualizing damage to the heart and other organs from COVID-19.

Applications on the company's Ziostation2 workstation help assess cardiovascular, respiratory, and pulmonary pathology, Ziosoft said. While the novel coronavirus was initially thought to be primarily a respiratory illness, conditions in other parts of the body, such as the brain and heart, have since come to the fore. Up to 24% of COVID-19 patients actually get myocardial injury or heart failure, the company noted.

Tools available for making the diagnosis include virtual bronchoscopy, CT cardiac function, and MR coronary analysis, Ziosoft said.

CT quantifies COVID-19 severity, ongoing conditions
Throughout this year's COVID-19 pandemic, chest CT has proved to be a valuable tool for diagnosing the illness in particular clinical situations. CT's...
Diabetes, hypertension boost COVID-19 stroke risk
Patients with diabetes and/or hypertension are at higher risk of COVID-19 brain complications such as bleeding and stroke, according to research to be...
Ziosoft reaches milestone with AI platform
Advanced visualization and artificial intelligence (AI) software developer Ziosoft said that over 2,500 installations of its software have been made worldwide.
Ziosoft lands FDA clearance for dual-energy CT software
Advanced visualization and artificial intelligence (AI) software developer Ziosoft has received U.S. Food and Drug Administration (FDA) 510(k) clearance...
Ziosoft touts new research bolstering CT CAC scoring
Software developer Ziosoft is highlighting research using its Ziostation2 advanced visualization platform to reduce reading times for CT coronary artery...

Copyright © 2020